APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Melanoma
Interventions
DRUG

APX005M

"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."

DRUG

Pembrolizumab

Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Apexigen America, Inc.

INDUSTRY

collaborator

Pyxis Oncology

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER